Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Treasury Shares (2021 - 2025)

Krystal Biotech's Treasury Shares history spans 5 years, with the latest figure at $331574.0 for Q4 2025.

  • For Q4 2025, Treasury Shares rose 141.14% year-over-year to $331574.0; the TTM value through Dec 2025 reached $331574.0, up 141.14%, while the annual FY2025 figure was $331574.0, 141.14% up from the prior year.
  • Treasury Shares for Q4 2025 was $331574.0 at Krystal Biotech, up from $56250.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $331574.0 in Q4 2025 and bottomed at $22200.0 in Q3 2024.
  • The 5-year median for Treasury Shares is $74100.0 (2022), against an average of $107716.1.
  • The largest annual shift saw Treasury Shares skyrocketed 643.99% in 2024 before it plummeted 82.97% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $98800.0 in 2021, then crashed by 32.59% to $66600.0 in 2022, then tumbled by 33.33% to $44400.0 in 2023, then surged by 209.68% to $137500.0 in 2024, then surged by 141.14% to $331574.0 in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Treasury Shares are $331574.0 (Q4 2025), $56250.0 (Q3 2025), and $56250.0 (Q1 2025).